Results 261 to 270 of about 5,668,323 (316)

Tacrolimus Concentration/Dose Ratio in Hematopoietic Cell Transplantation Recipients: An Exploratory Study of Metabolizer Phenotyping and Clinical Outcomes. [PDF]

Clin Transl Sci
da Costa-Junior LC, Tavares RCBDS, Izu M, Maradei SC, Moreira MCR, Nogueira MC, Lerner D, de Souza Fernandez T, Santos PCJL.   +8 more
europepmc   +1 more source

Allogeneic hematopoietic cell transplantation in mature T- or NK-lymphomas: a phase II clinical trial. [PDF]

Nat Commun
Rechache KA, Nunes NS, Sponaugle J, Xue E, Chai A, Combs R, Campos J, Feng X, Flomerfelt FA, Upadhyaya K, Telford W, Dawson B, Hughes TE, Shah SMS, Peluso A, McKeown C, Stokes A, Napier S, Sabina R, Wilder J, Cole K, Baruffaldi J, Cuellar-Rodriguez J, Gea-Banacloche J, Czech MM, Hyder MA, Kanakry CG, Dimitrova D, Kanakry JA.   +28 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Nonmyeloablative hematopoietic cell transplantation

Current Opinion in Oncology, 2001
The myeloablative doses of chemotherapy and radiation used with conventional allogeneic hematopoietic cell transplantation produce considerable morbidity and mortality that generally limit this treatment to patients younger than 55 years of age and in good general medical condition.
L, Feinstein, R, Storb
openaire   +2 more sources

Rituximab in hematopoietic cell transplantation

Expert Opinion on Biological Therapy, 2010
The success of rituximab therapy in managing B cell malignancies supports its widespread application in both autologous and allogeneic hematopoietic cell transplantation.We searched the PubMed database using the terms rituximab, stem cell transplant, autologous, or allogeneic and limited the search to clinical trials in English.
Sally, Arai, David B, Miklos
openaire   +2 more sources

Pediatric hematopoietic cell transplantation [PDF]

Journal of Pediatric Intensive Care, 2015
Hematopoietic cell transplantation is a potentially curative therapeutic modality for a wide range of pediatric malignant and nonmalignant diseases. Hematopoietic cell transplantation has evolved over time to include more indications for transplantation and broad-spectrum treatment and supportive care strategies. This review will address the process of
Kathryn, Walsh, Steven, Margossian, Christine N, Duncan   +2 more
openaire   +2 more sources

Hematopoietic Cell Transplantation for Hemoglobinopathies

Current Problems in Pediatric and Adolescent Health Care, 2008
Hematopoietic cell transplantation is the only curative therapy available for patients with the common and morbid inherited hemoglobin disorders, -thalassemia major and sickle cell anemia. As will be discussed, a number of complex independent factors need to be carefully weighed in making a decision as to whether the patient is an appropriate candidate
Lakshmanan, Krishnamurti, H Franklin, Bunn, Andrea M, Williams, Jakub, Tolar   +3 more
openaire   +2 more sources

Economics of hematopoietic cell transplantation

Blood, 2012
AbstractGiven the rapidly rising healthcare costs, it is important to understand the economic costs of hematopoietic cell transplantation (HCT), a procedure that is being used more frequently in the treatment of various hematologic disorders. Studies have reported a wide range of costs for HCT, from $36 000 to $88 000 (USD) for a single autologous ...
Nandita, Khera, Steven B, Zeliadt, Stephanie J, Lee   +2 more
openaire   +2 more sources

Hematopoietic Stem Cell Transplantation

Hospital Practice, 1993
The isolation, purification, and in vitro expansion of the hematopoietic stem cell have allowed pretransplant immunologic and genetic manipulation. As a result, rapid allogeneic or autologous hematologic reconstitution with minimal graft-versus-host disease is possible in patients receiving high-dose chemotherapy.
S, Jagannath, B, Barlogie, G, Tricot
openaire   +2 more sources

Neurologic Complications of Hematopoietic Cell Transplantation

Seminars in Neurology, 2004
Hematopoietic cell transplantation (HCT) involves the intravenous infusion of hematopoietic progenitor cells from the patient (autologous) or a human leukocyte antigen-matched donor (allogeneic). Before transplantation, the recipient undergoes a conditioning regimen with high-dose chemotherapy or radiotherapy (or both) to destroy a defective bone ...
Albert, Saiz, Francesc, Graus
openaire   +3 more sources